Background:
Past research has found that certain features of Wilms tumor—such as its size, biology, or response to treatment—can help predict the risk of relapse. Using this information, a variety of suitable chemotherapy drug combinations will be used in this study:
Vincristine stops cancer cells from dividing by interfering with their internal structure. Actinomycin (also called Dactinomycin) blocks the instructions cancer cells need to grow. Doxorubicin damages the DNA inside cancer cells, making it difficult for them to survive. Cyclophosphamide is a powerful drug that attacks cancer cell DNA to stop their growth. Irinotecan prevents cancer cells from copying their DNA, which stops them from multiplying.
The Trial:
This study compares different combinations of chemotherapy drugs to find out which treatments work best for children with different risk levels and cancer stages. It also looks at whether some children can safely skip chemotherapy after surgery, and how newer drug combinations compare to standard treatments used in the past. Participants will be randomly assigned to a treatment group based on their cancer stage.
This trial is not “blinded”, which means both you and your doctor will know which treatment you are receiving.
Basic Eligibility:
- Under 30 years old
- Must have newly diagnosed Wilms’ tumor with favorable histology (FHWT)
Additional eligibility criteria will apply. Please speak to your doctor.
Hospital / Cancer Centre | Principal Investigator | Location | Trial Status |
---|---|---|---|
Hospital / Cancer CentreIWK Health Centre | Principal InvestigatorDr. Craig Erker | LocationHalifax, NS | Trial StatusRecruiting |